Results 211 to 220 of about 267,118 (262)

A Comprehensive Meta-Analysis of the Cardiovascular Adverse Effects of Bispecific Antibody Therapy in Hematologic Malignancies. [PDF]

Pathophysiology
Tai D, Sandhu N, Dermarderosian A, Mkrtchyan N, Park D, Garg V, Nguyen A, Akhtari M.   +7 more
europepmc   +1 more source

Oral Astilbin Nanogels Modulate Senescence‐Associated CD4+ T Cells and Promote Treg Induction in Aged Mice with Colitis

Advanced Science, EarlyView.
Fluorinated β‐glucan/pectin nanogels enable colon‐targeted oral delivery of astilbin through gastrointestinal protection, β‐glucanase‐responsive release, mucus penetration, and prolonged retention. The released astilbin attenuates senescence‐associated features of CD4+ T cells and promotes Treg responses, while the nanogel matrix modulates the gut ...
Lei Zhao, Xinyun Zhang, Qian Ren, Xue Song, Meifang Zhao, Rongshen Wang, Haocheng Du, Yan Chen, Peigen Xu, Jiangyun Liu, Jian Zhang, Jingjing Ma   +11 more
wiley   +1 more source

Cell-free DNA fragmentomics and epigenomic profiling in hematologic malignancies: current evidence, translational limitations, and future directions. [PDF]

Transl Oncol
El-Sehrawy AAMA, Abdullah SS, Mamedova G, Rizaev J, Abdelrahim IM, Srivastav SK, Khaleel ZT, Jabir MS, Bainsal N, Smerat A.   +9 more
europepmc   +1 more source

A Living Multi‐Omics PDX Biobank of High‐Risk Sarcomas Reveals ecDNA‐Driven Oncogene Amplification in Osteosarcoma and Enables Preclinical Precision Oncology

Advanced Science, EarlyView.
A living multi‐omics sarcoma PDX biobank is enriched for high‐risk disease and preserves key patient tumor features at histopathological and molecular levels. Integrated profiling reveals ecDNA‐driven oncogene amplification in osteosarcoma and preferential retention of ecDNA during PDX evolution.
Weisong Zhao, Zhiwei Cheng, Kai Tian, Mengxiong Sun, Zhuoying Wang, Ming Jiao, Jens Luebeck, Kaiyuan Zhu, Xiao Zhang, Dongqing Zuo, Hongsheng Wang, Chongren Wang, Jiakang Shen, Xiaojun Ma, Gangyang Wang, Zongyi Wang, Jing Han, Kaiyuan Liu, Haoran Mu, Weiqi Ma, Yongyong Ren, Shibing Guo, Huangxin Tu, Lingfeng Yu, Yining Tao, Yu Lv, Hui Lu, Owen S. Chapman, Rishaan Kenkre, Lukas Chavez, Zhengdong Cai, Yuqin Yang, Wei Sun, Yafei Jiang, Yingqi Hua   +34 more
wiley   +1 more source

Erratum to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation

Haematologica
Zachary D. Epstein-Peterson, Esther Drill, Umut Aypar, Connie Lee Batlevi, Philip Caron, Ahmet Dogan, Pamela Drullinsky, John Gerecitano, Paul A. Hamlin, Caleb Ho, Allison Jacob, Ashlee Joseph, Leana Laraque, Matthew J. Matasar, Alison J. Moskowitz, Craig H. Moskowitz, Chelsea Mullins, Colette Owens, Gilles Salles, Heiko Schöder, David J. Straus, Anas Younes, Andrew D. Zelenetz, Anita Kumar   +23 more
doaj   +1 more source

Prospects and advances of PROTAC in the treatment of hematologic malignancies. [PDF]

Exp Hematol Oncol
Wang X, Zhang M, Mei H.
europepmc   +1 more source

A Biomimetic cRGDyk‐Engineered Platelet Nanoplatform for ACAD11 Delivery to Trigger Pyroptosis in Hepatocellular Carcinoma

Advanced Science, EarlyView.
A biomimetic platelet nanoplatform (OE‐ACAD11@R‐PLT) is developed for targeted hepatocellular carcinoma immunotherapy. By selectively delivering therapeutic plasmids, this system induces mitochondrial dysfunction and triggers robust NLRP3/Caspase‐1/GSDMD‐mediated pyroptosis in tumor cells.
Hongyi Bao, Wei Feng, Wei Zong, Yi Li, Xinyue Qin, Xinyue Wang, Yubo Yang, Guanhua Chen, Yiting Hou, Xuan Tan, Lin Chen, Ming Zhang, Feng Wang   +12 more
wiley   +1 more source

Impact of germline predisposition genes to hematologic malignancies on transplant outcomes and donor selection. [PDF]

Front Immunol
Li Z, Yang K, Zhang C, Wang X, Wang L, Li J, Wen X, Fei Q, Zhai J, Zhou Y, Ming Z, Song Y, Zhao Y, Wu T, Zheng Q.   +14 more
europepmc   +1 more source

A Dual‐Delivery System Designed to Overcome EV‐Mediated Ferroptosis Resistance for Efficient Solid Tumor Therapy

Advanced Science, EarlyView.
(A) Establishment and characterization of the osteosarcoma‐targeted dual‐delivery nanoplatform mBAP1/siENO1@LNP‐OTP for simultaneous regulation of BAP1 and ENO1 in tumor cells. (B) After intravenous administration, mBAP1/siENO1@LNP‐OTP preferentially accumulates at tumor sites through OTP‐mediated targeting.
Yechao Shen, Zhenguo Cao, Zenan Wang, Liang Chen, Jiahao Zhang, Linjie Zeng, Boren Tan, Hengyuan Li, Jiashan Lai, Jiangchu Lei, Fanglu Chen, Peng Lin, Zhenxuan Shao, Zhan Wang   +13 more
wiley   +1 more source

VCP‐Regulated LMF2 Stabilizes the Cholesterol Biosynthesis Enzyme HMGCS1 to Drive Cancer Progression and Confer Capecitabine Resistance in Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
LMF2 drives progression and capecitabine resistance in triple‐negative breast cancer (TNBC). Mechanistically, VCP prevents NBR1‐mediated autophagic degradation of LMF2, thereby stabilizing it. Stabilized LMF2 subsequently suppresses NDP52‐mediated autophagic degradation of HMGCS1, a rate‐limiting cholesterol biosynthesis enzyme.
Qian Zhao, Lisa Andriani, Yin‐Ling Zhang, Shao‐Ying Yang, Yun‐Xiao Ling, Min‐Ying Huang, Jia‐Yang Cai, Fang‐Lin Zhang, Xin Hu, A‐Yong Cao, Zhi‐Min Shao, Guang‐Yu Liu, Da‐Qiang Li   +12 more
wiley   +1 more source